Does the media prefer AMRX or SVRA?

In the previous week, Savara had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 4 mentions for Savara and 3 mentions for Amneal Pharmaceuticals. Savara's average media sentiment score of 0.86 beat Amneal Pharmaceuticals' score of 0.58 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amneal Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is SVRA or TWST more profitable?

Savara has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Savara N/A -87.19% -66.42% Twist Bioscience -19.85% -26.73% -19.15%

Does the media prefer SVRA or TWST?

In the previous week, Twist Bioscience had 2 more articles in the media than Savara. MarketBeat recorded 6 mentions for Twist Bioscience and 4 mentions for Savara. Twist Bioscience's average media sentiment score of 1.02 beat Savara's score of 0.86 indicating that Twist Bioscience is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Savara 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Twist Bioscience 3 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Savara (SVRA) Competitors

$5.20 +0.11 (+2.16%)

Closing price 04:00 PM Eastern

Extended Trading

$5.20 0.00 (-0.10%)

As of 06:32 PM Eastern

Compare

SVRA vs. KNSA, AMRX, CRNX, CPRX, and TWST

Should you buy Savara stock or one of its competitors? MarketBeat compares Savara with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Savara include Kiniksa Pharmaceuticals International (KNSA), Amneal Pharmaceuticals (AMRX), Crinetics Pharmaceuticals (CRNX), Catalyst Pharmaceuticals (CPRX), and Twist Bioscience (TWST). These companies are all part of the "pharmaceutical products" industry.

How does Savara compare to Kiniksa Pharmaceuticals International?

Savara (NASDAQ:SVRA) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

87.9% of Savara shares are held by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are held by institutional investors. 5.3% of Savara shares are held by insiders. Comparatively, 52.0% of Kiniksa Pharmaceuticals International shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Savara has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Savara's net margin of 0.00%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

In the previous week, Kiniksa Pharmaceuticals International had 2 more articles in the media than Savara. MarketBeat recorded 6 mentions for Kiniksa Pharmaceuticals International and 4 mentions for Savara. Kiniksa Pharmaceuticals International's average media sentiment score of 1.19 beat Savara's score of 0.86 indicating that Kiniksa Pharmaceuticals International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara presently has a consensus target price of $10.14, suggesting a potential upside of 95.05%. Kiniksa Pharmaceuticals International has a consensus target price of $60.86, suggesting a potential upside of 25.79%. Given Savara's stronger consensus rating and higher probable upside, research analysts clearly believe Savara is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Kiniksa Pharmaceuticals International	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.78

Kiniksa Pharmaceuticals International has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Kiniksa Pharmaceuticals International	$677.56M	5.49	$59.01M	$0.90	53.76

Summary

Kiniksa Pharmaceuticals International beats Savara on 11 of the 16 factors compared between the two stocks.

How does Savara compare to Amneal Pharmaceuticals?

Amneal Pharmaceuticals (NASDAQ:AMRX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

Amneal Pharmaceuticals has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amneal Pharmaceuticals	$3.02B	1.39	$72.06M	$0.38	34.66
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Amneal Pharmaceuticals has a net margin of 4.01% compared to Savara's net margin of 0.00%. Savara's return on equity of -87.19% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amneal Pharmaceuticals	4.01%	-313.96%	7.49%
Savara	N/A	-87.19%	-66.42%

Amneal Pharmaceuticals has a beta of 1.32, meaning that its stock price is 32% more volatile than the broader market. Comparatively, Savara has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market.

In the previous week, Savara had 1 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 4 mentions for Savara and 3 mentions for Amneal Pharmaceuticals. Savara's average media sentiment score of 0.86 beat Amneal Pharmaceuticals' score of 0.58 indicating that Savara is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amneal Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Savara	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Amneal Pharmaceuticals currently has a consensus target price of $15.17, suggesting a potential upside of 15.16%. Savara has a consensus target price of $10.14, suggesting a potential upside of 95.05%. Given Savara's stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amneal Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Comparatively, 5.3% of Savara shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Amneal Pharmaceuticals beats Savara on 8 of the 15 factors compared between the two stocks.

How does Savara compare to Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals (NASDAQ:CRNX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, institutional ownership, valuation, dividends, analyst recommendations and media sentiment.

Crinetics Pharmaceuticals currently has a consensus target price of $76.13, suggesting a potential upside of 114.14%. Savara has a consensus target price of $10.14, suggesting a potential upside of 95.05%. Given Crinetics Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Crinetics Pharmaceuticals is more favorable than Savara.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Savara has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Savara is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crinetics Pharmaceuticals	$7.70M	486.80	-$465.32M	-$5.13	N/A
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Savara has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%
Savara	N/A	-87.19%	-66.42%

Crinetics Pharmaceuticals has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Savara has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market.

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Savara shares are owned by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 5.3% of Savara shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Savara had 3 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 4 mentions for Savara and 1 mentions for Crinetics Pharmaceuticals. Savara's average media sentiment score of 0.86 beat Crinetics Pharmaceuticals' score of 0.62 indicating that Savara is being referred to more favorably in the news media.

Company	Overall Sentiment
Crinetics Pharmaceuticals	Positive
Savara	Positive

Summary

Crinetics Pharmaceuticals beats Savara on 8 of the 14 factors compared between the two stocks.

How does Savara compare to Catalyst Pharmaceuticals?

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Savara (NASDAQ:SVRA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, institutional ownership and profitability.

In the previous week, Savara had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 4 mentions for Savara and 1 mentions for Catalyst Pharmaceuticals. Catalyst Pharmaceuticals' average media sentiment score of 1.30 beat Savara's score of 0.86 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Catalyst Pharmaceuticals	Positive
Savara	Positive

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 5.3% of Savara shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has a beta of 0.72, indicating that its stock price is 28% less volatile than the broader market. Comparatively, Savara has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Catalyst Pharmaceuticals has higher revenue and earnings than Savara. Savara is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$596.96M	6.40	$214.33M	$1.74	17.95
Savara	N/A	N/A	-$118.84M	-$0.56	N/A

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Savara's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%
Savara	N/A	-87.19%	-66.42%

Catalyst Pharmaceuticals currently has a consensus target price of $32.00, suggesting a potential upside of 2.47%. Savara has a consensus target price of $10.14, suggesting a potential upside of 95.05%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Catalyst Pharmaceuticals beats Savara on 11 of the 16 factors compared between the two stocks.

How does Savara compare to Twist Bioscience?

Savara (NASDAQ:SVRA) and Twist Bioscience (NASDAQ:TWST) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, dividends, valuation, profitability and institutional ownership.

Twist Bioscience has higher revenue and earnings than Savara. Twist Bioscience is trading at a lower price-to-earnings ratio than Savara, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Savara	N/A	N/A	-$118.84M	-$0.56	N/A
Twist Bioscience	$376.57M	11.06	-$77.67M	-$1.33	N/A

87.9% of Savara shares are held by institutional investors. 5.3% of Savara shares are held by company insiders. Comparatively, 3.1% of Twist Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Savara has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Twist Bioscience has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market.

Savara has a net margin of 0.00% compared to Twist Bioscience's net margin of -19.85%. Twist Bioscience's return on equity of -26.73% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Savara	N/A	-87.19%	-66.42%
Twist Bioscience	-19.85%	-26.73%	-19.15%

In the previous week, Twist Bioscience had 2 more articles in the media than Savara. MarketBeat recorded 6 mentions for Twist Bioscience and 4 mentions for Savara. Twist Bioscience's average media sentiment score of 1.02 beat Savara's score of 0.86 indicating that Twist Bioscience is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Savara	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Twist Bioscience	3 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Savara currently has a consensus price target of $10.14, suggesting a potential upside of 95.05%. Twist Bioscience has a consensus price target of $58.00, suggesting a potential downside of 13.26%. Given Savara's stronger consensus rating and higher probable upside, research analysts plainly believe Savara is more favorable than Twist Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88
Twist Bioscience	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Savara and Twist Bioscience tied by winning 8 of the 16 factors compared between the two stocks.

Get Savara News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVRA vs. The Competition

Export

Metric	Savara	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.07B	$3.02B	$6.41B	$12.58B
Dividend Yield	N/A	1.97%	2.75%	5.26%
P/E Ratio	-9.29	17.54	21.25	26.28
Price / Sales	N/A	341.85	561.56	114.71
Price / Cash	N/A	56.31	43.49	56.90
Price / Book	6.05	6.31	10.60	7.33
Net Income	-$118.84M	$75.84M	$3.56B	$337.06M
7 Day Performance	3.59%	3.33%	2.97%	3.43%
1 Month Performance	7.22%	2.06%	6.25%	7.24%
1 Year Performance	132.14%	32.76%	36.72%	37.97%

Savara Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVRA Savara	2.2364 of 5 stars	$5.20 +2.2%	$10.14 +95.1%	+138.4%	$1.07B	N/A	N/A	20
KNSA Kiniksa Pharmaceuticals International	4.5546 of 5 stars	$53.24 flat	$60.86 +14.3%	+86.5%	$4.10B	$677.56M	59.16	220	Positive News
AMRX Amneal Pharmaceuticals	4.2023 of 5 stars	$12.42 flat	$15.17 +22.1%	+79.6%	$3.96B	$3.02B	32.69	8,500	Analyst Downgrade
CRNX Crinetics Pharmaceuticals	3.2867 of 5 stars	$36.80 flat	$76.13 +106.9%	+20.4%	$3.88B	$7.70M	N/A	210
CPRX Catalyst Pharmaceuticals	4.2185 of 5 stars	$31.26 flat	$32.17 +2.9%	+27.5%	$3.83B	$588.99M	17.97	80	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVRA) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Savara (SVRA) Competitors

SVRA vs. KNSA, AMRX, CRNX, CPRX, and TWST

How does Savara compare to Kiniksa Pharmaceuticals International?

Summary

How does Savara compare to Amneal Pharmaceuticals?

Summary

How does Savara compare to Crinetics Pharmaceuticals?

Summary

How does Savara compare to Catalyst Pharmaceuticals?

Summary

How does Savara compare to Twist Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Savara (SVRA) Competitors

SVRA vs. KNSA, AMRX, CRNX, CPRX, and TWST

How does Savara compare to Kiniksa Pharmaceuticals International?

Do insiders and institutionals hold more shares of SVRA or KNSA?

Which has more risk & volatility, SVRA or KNSA?

Is SVRA or KNSA more profitable?

Does the media refer more to SVRA or KNSA?

Do analysts recommend SVRA or KNSA?

Which has higher valuation and earnings, SVRA or KNSA?

Summary

How does Savara compare to Amneal Pharmaceuticals?

Which has better earnings & valuation, AMRX or SVRA?

Is AMRX or SVRA more profitable?

Which has more risk & volatility, AMRX or SVRA?

Does the media prefer AMRX or SVRA?

Do analysts rate AMRX or SVRA?

Do institutionals and insiders hold more shares of AMRX or SVRA?

Summary

How does Savara compare to Crinetics Pharmaceuticals?

Do analysts prefer CRNX or SVRA?

Which has higher earnings and valuation, CRNX or SVRA?

Is CRNX or SVRA more profitable?

Which has more risk & volatility, CRNX or SVRA?

Do institutionals & insiders hold more shares of CRNX or SVRA?

Does the media refer more to CRNX or SVRA?

Summary

How does Savara compare to Catalyst Pharmaceuticals?

Does the media prefer CPRX or SVRA?

Do institutionals & insiders have more ownership in CPRX or SVRA?

Which has more volatility and risk, CPRX or SVRA?

Which has better valuation and earnings, CPRX or SVRA?

Is CPRX or SVRA more profitable?

Do analysts rate CPRX or SVRA?

Summary

How does Savara compare to Twist Bioscience?

Which has preferable valuation & earnings, SVRA or TWST?

Do institutionals & insiders hold more shares of SVRA or TWST?

Which has more risk and volatility, SVRA or TWST?

Is SVRA or TWST more profitable?

Does the media prefer SVRA or TWST?

Do analysts rate SVRA or TWST?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVRA vs. The Competition

Savara Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools